Sarepta Therapeutics, Inc. (SRPT)
17.73
-0.45
(-2.48%)
USD |
NASDAQ |
Oct 23, 16:00
17.70
-0.02
(-0.14%)
After-Hours: 20:00
Sarepta Therapeutics Enterprise Value : 2.130B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.130B |
| October 22, 2026 | 2.178B |
| October 21, 2026 | 2.218B |
| October 20, 2026 | 2.282B |
| October 19, 2026 | 2.130B |
| October 16, 2026 | 2.064B |
| October 15, 2026 | 2.136B |
| October 14, 2026 | 2.035B |
| October 13, 2026 | 2.001B |
| October 12, 2026 | 2.099B |
| October 09, 2026 | 2.143B |
| October 08, 2026 | 2.181B |
| October 07, 2026 | 2.106B |
| October 06, 2026 | 2.086B |
| October 05, 2026 | 2.105B |
| October 02, 2026 | 2.106B |
| October 01, 2026 | 2.113B |
| September 30, 2026 | 2.182B |
| September 29, 2026 | 2.226B |
| September 28, 2026 | 2.243B |
| September 25, 2026 | 2.229B |
| September 24, 2026 | 2.200B |
| September 23, 2026 | 2.259B |
| September 22, 2026 | 2.455B |
| September 21, 2026 | 2.385B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.381B |
| September 17, 2026 | 2.441B |
| September 16, 2026 | 2.344B |
| September 15, 2026 | 2.446B |
| September 14, 2026 | 2.467B |
| September 11, 2026 | 2.417B |
| September 10, 2026 | 2.425B |
| September 09, 2026 | 2.583B |
| September 08, 2026 | 2.469B |
| September 04, 2026 | 2.634B |
| September 03, 2026 | 2.686B |
| September 02, 2026 | 2.709B |
| September 01, 2026 | 2.510B |
| August 31, 2026 | 2.479B |
| August 28, 2026 | 2.461B |
| August 27, 2026 | 2.538B |
| August 26, 2026 | 2.313B |
| August 25, 2026 | 2.256B |
| August 24, 2026 | 2.172B |
| August 21, 2026 | 2.242B |
| August 20, 2026 | 2.287B |
| August 19, 2026 | 2.341B |
| August 18, 2026 | 2.161B |
| August 17, 2026 | 2.178B |
| August 14, 2026 | 2.169B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.578B |
| Moderna, Inc. | 75.99B |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Rocket Pharmaceuticals, Inc. | -8.104M |
| Intellia Therapeutics, Inc. | 1.205B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.89M |
| Revenue (Quarterly) | 401.25M |
| Total Expenses (Quarterly) | 406.14M |
| EPS Diluted (Quarterly) | -0.0464 |
| Gross Profit Margin (Quarterly) | 60.18% |
| Profit Margin (Quarterly) | -1.22% |
| Earnings Yield | -16.34% |
| Normalized Earnings Yield | -9.658 |